Health Trials

Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

1

Review clinical trials related to Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.

Participants needed: 390
Trial details
Phase: Phase 2, Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai JMT-Bio Inc.Updated: Apr 3, 2025
Eligibility criteria

1. Able to understand and voluntarily sign the written informed consent form (IC...

Prior treatment with an EGFR inhibitor or MET inhibitor; [+7]

Read more